Document is current

Article History

Received: 6 January 2026

Accepted: 26 February 2026

First Online: 17 March 2026

Declarations

:

: The research protocol was approved by the Ethics Committee of Amsterdam UMC (#2021.0534). Participants provided written informed consent before the interview.

: Not applicable.

: JS is a recipient of the Alzheimer Nederland InterAct grant (#WE.08-2024-01) and the ZonMw Impact Explorer Dementia (#10510462310005). JS wrote a book for a layman’s audience about the personal impact of dominantly inherited AD, for which she received grants or contracts from Aegon Nederland and Alzheimer Nederland and royalties from Uitgeverij Prometheus. JS is a member of the advisory board for the National Dementia Strategy of the Dutch Ministry of Health, Welfare and Sport.As of 1-11-2025, WF is executive director at Alzheimer Nederland, Amersfoort the Netherlands. Before 1-11-2025, research programs of Wiesje van der Flier have been funded by ZonMW, NWO, EU-JPND, EU-IHI, Alzheimer Nederland, Hersenstichting CardioVascular Onderzoek Nederland, Health~Holland, Topsector Life Sciences & Health, stichting Dioraphte, Noaber foundation, Pieter Houbolt Fonds, Gieskes-Strijbis fonds, stichting Equilibrio, Edwin Bouw fonds, Pasman stichting, Philips, Biogen MA Inc, Novartis-NL, Life-MI, AVID, Roche BV, Eli-Lilly-NL, Fujifilm, Eisai, Combinostics. WF is recipient of ABOARD, which is a public-private partnership receiving funding from ZonMW (#73305095007) and Health~Holland, Topsector Life Sciences & Health (PPP-allowance; #LSHM20106). Before 1-11-2025, WF has been an invited speaker at Biogen MA Inc, Danone, Eisai, WebMD Neurology (Medscape), NovoNordisk, Springer Healthcare, European Brain Council. WF has been consultant to Oxford Health Policy Forum CIC, Roche, Biogen MA Inc, Eisai, Eli-Lilly, Owkin France, Nationale Nederlanden Ventures. WF has participated in advisory boards of Biogen MA Inc, Roche, and Eli Lilly. 2024-2025, WF has been member of the steering committee of phase 3 EVOKE/EVOKE+ studies (NovoNordisk). In 2025, WF has been member of the steering committee op phase 3 Trontinemab study (Roche). All funding has been paid to Amsterdam UMC. WF was associate editor of Alzheimer, Research & Therapy in 2020/2021. WF was associate editor at Brain 2021-2025. WF is chair of the Scientific Leadership Group of InRAD. WF is member of Supervisory Board (Raad van Toezicht) Trimbos Instituut.LV has been an invited speaker at an event organized by the Schwabe Group, fees were paid to her institution. Her research has been funded by ZonMW, Alzheimer Nederland, Health~Holland Topsector Life Sciences & Health, Eisai, and Amsterdam Public Health research institute.None of the other authors have conflicts of interest to disclose.